Schonfeld Strategic Advisors LLC Relmada Therapeutics, Inc. Transaction History

Schonfeld Strategic Advisors LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$2.48 - $3.79 $271,088 - $414,284	109,310 New	109,310 $327,000
Q4 2022 Feb 14, 2023	SELL	$2.17 - $35.84 $163,184 - $2.7 Million	-75,200 Reduced 49.97%	75,300 $262,000
Q3 2022 Nov 14, 2022	BUY	$18.3 - $37.02 $2.75 Million - $5.57 Million	150,500 New	150,500 $5.57 Million
Q1 2022 May 16, 2022	SELL	$16.72 - $26.99 $916,255 - $1.48 Million	-54,800 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$16.93 - $26.82 $984,276 - $1.56 Million	-58,138 Reduced 51.48%	54,800 $1.24 Million
Q3 2021 Nov 16, 2021	BUY	$21.86 - $34.77 $1.21 Million - $1.92 Million	55,177 Added 95.53%	112,938 $2.96 Million
Q2 2021 Aug 16, 2021	BUY	$29.55 - $39.15 $96,333 - $127,629	3,260 Added 5.98%	57,761 $1.85 Million
Q1 2021 May 17, 2021	BUY	$31.52 - $39.28 $1.72 Million - $2.14 Million	54,501 New	54,501 $1.92 Million

12.3M

229K

138K

Ticker RLMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,608,500
Market Cap $10.9M
Description
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that ...

Get notified when there are updates to the investment portfolio of Schonfeld Strategic Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Schonfeld Strategic Advisors LLC with notifications on news.